Our breakthrough technology combines synthetic and stem cell biology, offering limitless possibilities. Enabling a new generation of cell therapies, providing the best human cells for research and drug discovery, and allowing the control of advanced synthetic biology circuits for biomanufacturing.
Operating from state-of-the-art research facilities in Loughborough and BioCity Nottingham, UK, we are a leading Contract Research Organisation, providing medicinal and synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.
The cornerstone of our success is built upon regular and open communication with our clients, the highest integrity in our business relationships, high quality yet cost effective services, and the flexibility that we offer – we can undertake projects from one week in duration to multi-year, multi-FTE collaborations. Our goal is to support you in producing excellence in your own research, achieving your milestones and business objectives on time and to budget.
We offer a range of competitively priced services tailored to the specific requirements of our clients. These include Medicinal Chemistry and Contract Research (FTE).
Charnwood Molecular offers support to drug discovery efforts within the pharmaceutical and biotechnology industries. This service covers Lead Discovery and Lead Optimisation. Our pharma-trained medicinal chemists have experience in many therapeutic areas.
Presented with a target molecule with little or no literature precedent, we will investigate potential methods of preparation, optimisation and scale-up, according to your needs.
Club Quarters Hotels
Club Quarters Hotels are full service hotels located in world-class cities in the U.S. and London. Designed for business and urban travelers, we have the accommodations, amenities and services needed to make your stay productive, enjoyable, and hassle-free.
Curileum Discovery Ltd is a new regenerative medicine company in London focused on identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues. Effective tissue regeneration requires activation of endogenous healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal.
We are applying three decades of stem cell drug discovery and development experience to unlock a whole new range of therapeutic targets to kill defective stem cells and to activate healthy stem cells to restore health to the intestine.
CytoSeek's mission is to use Artificial Membrane Binding Protein technology to deliver the potential of the next generation of cell therapies, with a focus on treating solid tumours.
The company was founded in November 2017 to commercialise the technology developed by Professor Adam Perriman and his team at the University of Bristol.
CytoSeek is now engaged in proof of principle studies for multiple product candidates, and is seeking to enhance cell therapies against solid tumours.
We create technologies that drive human progress.
Our story began with a belief and a passion: that everybody should have easy access to the best technology anywhere in the world. That was in 1984 in Michael Dell’s University of Texas dorm room. Today, Dell Technologies is instrumental in changing the digital landscape the world over.
We are among the world’s leading technology companies helping to transform people’s lives with extraordinary capabilities. From hybrid cloud solutions to high-performance computing to ambitious social impact and sustainability initiatives, what we do impacts everyone, everywhere.
Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities. www.selcia.com
- 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)
- GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance
- Stable Labelling (13C, 2H, 15N) Internal Standards, Metabolites and Impurities
- GLP Analysis Certification and Problem Solving including GLP NMR
Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration
Evgen Pharma plc
Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation.
There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods.
Evgen exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.
Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion provides contract services include...
- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services
Galen are a global pharmaceutical company selling medicines worldwide in the areas of pain management, dermatology and gastroenterology, and partner with like-minded companies to accomplish this.
Established in 1968, with headquarters in Craigavon, Northern Ireland, Galen works in partnership with healthcare professionals and patients to advance human health. They actively seek new markets and new opportunities, toward fulfilling their vision of creating a truly international pharmaceutical company from our base in Northern Ireland.
By combining innovation in product development with competitive pricing, Galen works in partnership with healthcare professionals and patients to create real, long-term value, a major factor in our success to date.
Galen expertise lies in
- sales, marketing and launch excellence
- market access
- regulatory affairs, pharmacovigilance and medical affairs
- supply chain and logistics.